Computer Modeling to Aid Fight Against Diabetes

The NOD model to be developed by Entelos (Foster City, CA, USA) is designed to bridge this gap by translating results from pre-clinical animal studies into predictions for the outcome of human trials.

The model will be built in collaboration with the American Diabetes Association (ADA) and a scientific advisory board they select to guide and oversee the development of the NOD PhysioLab platform.

Dr. Mikhail Gishizky, Entelos CSO, said, "Translational medicine--translating observations made in pre-clinical animal model systems to human in vivo responses--is a complex issue posing significant challenges to the development of therapeutics for treating human disease. Although numerous therapies have been shown to inhibit the development of type 1 diabetes in the NOD mouse, success in advancing these therapies to human patients has been limited. Through the use of predictive mathematical models, the research community will have a significant scientific advancement which will ultimately improve the rationale for taking novel interventions into humans.”




Related Links:
Entelos